Twist Bioscience Corp (NASDAQ: TWST)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001581280
P/B 3.91
P/E -23.79
P/S 4.91
Market Cap 1.85 Bn
ROIC (Qtr) -24.24
Div Yield % 0.00
Rev 1y % (Qtr) 16.88
Total Debt (Qtr) 90.57 Mn
Debt/Equity (Qtr) 0.19

About

Twist Bioscience Corporation (TWST) is a biotechnology company operating in the synthetic biology industry. Its primary business activities involve the design, synthesis, and manufacturing of synthetic DNA, RNA, and proteins for various applications, spanning healthcare, food and agriculture, industrial chemicals, and academic research. The company generates revenue through its synthetic biology and next-generation sequencing (NGS) tools product lines, as well as biopharma services for antibody discovery, optimization, and development. Twist Bioscience's...

Read more

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 183.05M provide 13.24x coverage of short-term debt 13.82M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 546.24M provides 6.03x coverage of total debt 90.57M, indicating robust asset backing and low credit risk.
  • Long-term investments of 56.71M provide solid 0.74x coverage of long-term debt 76.75M, indicating strategic financial planning.
  • Cash reserves of 183.05M provide ample 73.22x coverage of acquisition spending 2.50M, enabling strategic growth opportunities.
  • Tangible assets of 546.24M provide robust 8.22x coverage of other current liabilities 66.49M, indicating strong asset backing.

Cons

  • Investment activities of (24.76M) provide weak support for R&D spending of 80.28M, which is -0.31x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (47.63M) shows concerning coverage of stock compensation expenses of 64.46M, with a -0.74 ratio indicating potential earnings quality issues.
  • High receivables of 57.02M relative to inventory of 28.31M (2.01 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • Operating cash flow of (47.63M) provides minimal -66.24x coverage of tax expenses of 719000, suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Operating earnings of (76.95M) show weak coverage of depreciation charges of 24.83M, with a -3.10 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 216.83 Bn 33.00 4.96 35.68 Bn
2 DHR Danaher Corp /De/ 162.47 Bn 46.38 6.69 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 56.88 Bn 55.36 13.65 1.09 Bn
4 A Agilent Technologies, Inc. 39.82 Bn 32.64 5.87 3.41 Bn
5 IQV Iqvia Holdings Inc. 38.85 Bn 30.28 2.44 15.19 Bn
6 NTRA Natera, Inc. 31.32 Bn -101.29 14.80 0.18 Bn
7 MTD Mettler Toledo International Inc/ 28.99 Bn 34.68 7.35 2.21 Bn
8 WAT Waters Corp /De/ 22.92 Bn 35.32 7.38 1.49 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.71 2.69
EV to Cash from Ops. -36.53 18.14
EV to Debt 19.21 52.51
EV to EBIT -22.61 19.22
EV to EBITDA -15.61 4.35
EV to Free Cash Flow [EV/FCF] -23.00 2.84
EV to Market Cap 0.94 1.52
EV to Revenue 4.62 4.79
Price to Book Value [P/B] 3.91 1.34
Price to Earnings [P/E] -23.79 22.02

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -1.96
Dividend Payout Ratio % 0.00 2.83
Dividend per Basic Share 0.00 0.19
FCF Dividend Payout Ratio % 0.00 1.92
Interest Coverage 0.00 -126.58

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -451.69 -31.50
Cash and Equivalents Growth (1y) % -19.12 21.37
Dividend Growth (1y) % 0.00 0.24
EBIAT Growth (1y) % 62.79 -55.24
EBITDA Growth (1y) % 40.88 -447.96
EBIT Growth (1y) % 63.03 -40.50
EBT Growth (1y) % 63.03 -70.94
EPS Growth (1y) % 63.89 -70.02
FCF Growth (1y) % -9.34 56.33
Gross Profit Growth (1y) % 43.23 185.11

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.59 0.56
Cash Payout Ratio 0.00 0.01
Cash Ratio 2.00 1.21
Current Ratio 3.64 2.64
Debt to Equity Ratio 0.19 -0.80
Interest Cover Ratio 0.00 -126.58
Times Interest Earned 0.00 -126.58

Profitability

Metric Value Industry Percentile
EBITDA Margin % -13.80 -129.91
EBIT Margin % -20.43 -156.71
EBT Margin % -20.43 -162.23
Gross Margin % 50.70 47.70
Net Profit Margin % -20.60 -189.30